Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 17Terminated 7Recruiting 4Withdrawn 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Carcinoma, Renal Cell 2Neoplasm Metastasis 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × tivozanib × Clear all
NCT01769885 2022-08-15

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Roswell Park Cancer Institute

Phase NA Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT01728181 2013-07-25

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

University of Utah

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Disease

NCT01834183 2013-06-19

Tivozanib + Gemcitabine in Metastatic RCC

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡